Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: Results of a phase 1 study

Leukemia and Lymphoma

Volumn 54, Issue 9, 2013, Pages 1915-1920

  Abramson, Jeremy S ^a,b   Takvorian, Ronald W ^a,b   Fisher, David C ^b,c   Feng, Yang ^d   Jacobsen, Eric D ^b,c   Brown, Jennifer R ^b,c   Barnes, Jeffrey A ^a,b   Neuberg, Donna S ^d   Hochberg, Ephraim P ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Department of Medical Oncology ^*  (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Follicular lymphoma; Mantle cell lymphoma; Marginal zone lymphoma; Non Hodgkin lymphoma; Nucleoside analog

Indexed keywords

CLOFARABINE; RITUXIMAB;

ABDOMINAL DISCOMFORT; ADULT; AGED; ANEMIA; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HEADACHE; HUMAN; HYPOPHOSPHATEMIA; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR VOLUME; VOMITING; WALDENSTROEM MACROGLOBULINEMIA; WEAKNESS;

ADENINE NUCLEOTIDES; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ARABINONUCLEOSIDES; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84883022727     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.763397     Document Type: Article

References (24)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. C A Cancer J Clin 2012;62:10-29.
2. Lenz G, Hiddemann W, Dreyling M. The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer 2004;101:883-893.
3. Sigal D S, Miller H J, Schram E D, et al. Beyond hairy cell :The activity of cladribine in other hematologic malignancies. Blood 2010;116:2884-2896.
4. Parker WB, Shaddix SC, Chang CH, et al. Eff ects of 2-chloro-9-(2-deoxy- 2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5 '-triphosphate. Cancer Res 1991;51:2386-2394.
5. Xie K C, Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl) adenine. Cancer Res 1996;56:3030-3037.
6. LotfiK, Mansson E, Spasokoukotskaja T, et al. Biochemical pharmacology and resistance to 2-chloro-2 '-arabino-fluoro-2 '-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res 1999;5:2438-2444.
7. Bonate PL, Arthaud L, Cantrell WR Jr, et al. Discovery and development of clofarabine :A nucleoside analogue for treating cancer. Nat Rev Drug Discov 2006;5:855-863.
8. Carson DA, Wasson DB, Esparza LM, et al. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2 '-arabino-fluoro-2 '-deoxyadenosine. Proc Natl Acad Sci USA 1992;89:2970-2974.
9. Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly aff ecting the mitochondria. Blood 2000;96:3537-3543.
10. Blum KA, Hamadani M, Phillips GS, et al. Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. Leuk Lymphoma 2009;50:349-356.
11. Nabhan C, Davis N, Bitran JD, et al. Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients. Cancer 2011;117:1490-1497.
12. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
13. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin ' s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
14. Redman JR, Cabanillas F, Velasquez WS, et al. Phase II trial of fludarabine phosphate in lymphoma:An eff ective new agent in lowgrade lymphoma. J Clin Oncol 1992;10:790-794.
15. Hochster H S, Kim K M, Green M D, et al. Activity of fludarabine in previously treated non-Hodgkin ' s low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study. J Clin Oncol 1992;10:28-32.
16. Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005;23:694-704.
17. Tulpule A, Schiller G, Harvey-Buchanan LA, et al. Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin' s lymphoma. Cancer 1998;83:2370-2376.
18. Kong LR, Huang CF, Hakimian D, et al. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin' s lymphoma. Cancer 1998;82:957-964.
19. Nagai H, Ogura M, Kusumoto S, et al. Cladribine combined with rituximab (R-2-CdA) therapy is an eff ective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma. Eur J Haematol 2011;86:117-123.
20. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-115.
21. Tobinai K, Watanabe T, Ogura M, et al. Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin ' s lymphoma. J Clin Oncol 2006;24:174-180.
22. Goy A, Bernstein S H, Kahl B S, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009;20:520-525.
23. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator ' s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822-3829.
24. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009;145:344-349.